Durvalumab(Synonyms: 德瓦鲁单抗; MEDI 4736)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Durvalumab (Synonyms: 德瓦鲁单抗; MEDI 4736) 纯度: 99.60%

Durvalumab (MEDI 4736) 是一种人源化的抗 PD-L1 蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断 PD-L1 与 PD-1 和 CD80 结合， IC50 分别为 0.1 和 0.04 nM。

Durvalumab(Synonyms: 德瓦鲁单抗; MEDI 4736)

Durvalumab Chemical Structure

CAS No. : 1428935-60-7

规格 价格 是否有货 数量
1 mg ￥2700 In-stock
5 mg ￥5700 In-stock
25 mg ￥21650 询价
50 mg ￥35000 询价
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

生物活性

Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody[1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively[2].

IC50 & Target

IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)[2]
体内研究
(In Vivo)

Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells[2]
Dosage: 5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
Administration: Administration i.p.; twice per week; for 3 weeks
Result: Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.

Clinical Trial

CAS 号

1428935-60-7
中文名称

度伐单抗；德瓦鲁单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.

    [2]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务